

The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles

Levent Kilic, Abdulsamet Erden, Clifton O. Bingham III, Laure Gossec, and Umut Kalyoncu

ABSTRACT. Objective. Patient-reported outcomes (PRO) in rheumatoid arthritis (RA) provide important information regarding disease effect. The study objective was to assess the frequency of PRO use in recent RA studies and compare results with a previous systematic review (SR) in 2005–2007.

Methods. An SR was performed in PubMed MEDLINE (January 2015). Publications were identified using these MEDICAL Subject Headings terms: “arthritis, rheumatoid” with a limitation to “humans,” “all adults: 19+ years,” “English,” “published in the last 2 years,” and “clinical trials.” All studies were assessed, whatever their designs. All PRO reported in publications were classified according to general domains of health by 2 authors. Statistics were descriptive.

Results. Two hundred fifty articles were analyzed. Of them, 113 (45.2%) were randomized controlled trials; 138 different PRO were reported. The most frequent PRO, similar to the 2007 SR, were function (68.0%), pain (40.0%), patient’s global assessment (49.2%), and health-related quality of life (18.4%). Fatigue (14.4%), morning stiffness (10.0%), psychological status (9.6%), productivity losses (6.4%), utility (5.2%), sleep disturbance (2.4%), and coping (2.0%) were rarely reported. Although frequent domains were reported using well-validated questionnaires, the others were reported using heterogeneous questionnaires.

Conclusion. The PRO collected and reported in RA studies are remarkably consistent with those seen in 2005–2007, and reflect the existing RA Core Set measures. Other domains of health prioritized by patients including fatigue, psychological status, productivity losses, sleep disturbance, and coping remain rarely reported. Further, heterogeneity in outcome measures used presents challenges in interpreting true disease effect and response to therapy. (J Rheumatol First Release April 15 2016; doi:10.3899/jrheum.151177)

Key Indexing Terms:

RHEUMATOID ARTHRITIS
PATIENT-REPORTED

SYSTEMATIC REVIEW
OUTCOMES MEASURES

A comprehensive assessment of patients is one of the major steps to determine an appropriate treatment course in inflammatory diseases such as rheumatoid arthritis (RA). In general,

From the Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); Department of Rheumatology, AP-HP, Pitié Salpêtrière Hospital, Paris, France.

L. Kilic, MD, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; A. Erden, MD, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; C.O. Bingham III, MD, Professor, Division of Rheumatology, Department of Medicine, Johns Hopkins University; L. Gossec, MD, Professor, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d’Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and Department of Rheumatology, AP-HP, Pitié Salpêtrière Hospital; U. Kalyoncu, MD, Associate Professor, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Hacettepe University, and Division of Rheumatology, Department of Medicine, Johns Hopkins University.

Address for correspondence to Dr. L. Kilic, Division of Rheumatology, Department of Internal Medicine, Hacettepe University Hospital, Sıhhiye Ankara 06100, Turkey. E-mail: drleventkilic@yahoo.com

Accepted for publication March 7, 2016.

there are 3 ways to determine the condition of patients with RA: clinician-reported outcomes (e.g., clinical examination), patient-reported outcomes (PRO), and “objective” assessments of pathophysiological manifestations of disease (e.g., laboratory investigations, imaging). In RA, laboratory measures such as erythrocyte sedimentation rate and C-reactive protein (CRP) do not correlate well with other markers of disease activity. In contrast, other chronic conditions such as renal failure have laboratory indices as outcomes that reflect overall renal function (e.g., glomerular filtration rate)¹. Thus, in RA, both clinician-reported outcomes and PRO provide additional information as part of the core set of measures recommended to assess disease activity, severity, and response to treatment in randomized controlled trials (RCT) and clinical practice^{2,3,4}. Notwithstanding, there are often disparities between physician and patient assessments of disease⁵. Indeed, some domains of health important to patients such as fatigue, sleep, or well-being may not be considered essential by physicians^{6,7,8}. A prior systematic review (SR) evaluated the range and frequency of PRO domains and questionnaires in 109 RA studies published between 2005 and 2007⁹. In that report, the

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.

only domains frequently assessed in RCT or other studies⁹ were physical function (83.4%), patient's global assessment (PtGA; 63.3%), and pain (55.9%). Other domains assessed far less frequently were morning stiffness (26.6%), health-related quality of life (HRQOL; 19.2%), utility (16.5%), fatigue (13.7%), self-reported painful joint count (9.1%), psychological status (7.3%), coping (6.4%), productivity losses (5.5%), well-being (3.6%), sleep disturbance (1.8%), and leisure (0.9%). Over the last decade, there have been substantial advances toward awareness of importance of PRO in rheumatology^{10,11}. It is unknown whether these advances have translated into their increased incorporation or reporting in RCT.

The objective of our study was to assess PRO reported in RA studies published in the last 2 years and to compare the frequency of questionnaires and domains reported with our prior SR of PRO in RA studies.

MATERIALS AND METHODS

To obtain all recently published articles reporting any type of PRO in RA, we conducted an SR using the PubMed MEDLINE database on January 1, 2015. To make a more direct comparison with the results from our prior SR, we did not include EMBASE or other databases for our search. Publications were identified through a search that used the following exploded Medical Subject Headings terms: "arthritis, rheumatoid" with limitations to "humans," "all adults: 19+ years," "English," "published in the last 2 years," and "clinical trials." Publications were limited to articles referenced in PubMed in the prior 2 years (January 1, 2013, to December 31, 2014) to obtain an overview of the status of recent research.

Inclusion criteria were articles reporting any type of clinical study that included patients with RA and reported PRO results. Articles were excluded if they did not concern RA or if they did not report any patient-based outcome measures (e.g., articles reporting only laboratory outcomes, radiographic scores, or genetic information). Reviews, editorials, and letters were excluded because we were interested in obtaining information from primary original research articles. If there was more than 1 publication related to a single RCT (e.g., extension of main clinical study, pooled, or subanalyses), we selected the study that included the most PRO.

The initial selection process by 1 author (AE) was based on titles and abstracts of the articles, followed by full text review. Data were extracted from the full-text articles. Publications were assessed using a checklist of items developed by the 2 reviewers, LK and UK. Reviewers were not blinded to the journal name or authors. Data were obtained on year of publication, study design (RCT or other studies), and number of patients. Demographic data such as percentage of women, mean age, mean disease duration, treatments under evaluation, and maximum duration of followup were recorded for each report.

Patient-reported outcomes. All PRO measures were noted. Outcome measures that were not patient-reported, such as biological results (e.g., CRP, rheumatoid factor, anticyclic citrullinated peptide antibodies) or radiographs, were not assessed. If available, composite indices such as the Disease Activity Score (DAS)¹², American College of Rheumatology (ACR) response criteria¹³, European League Against Rheumatism (EULAR) response criteria¹⁴, Simplified Disease Activity Index (SDAI)¹⁵, or Clinical Disease Activity Index (CDAI)¹⁶ were noted. These composite indices included PRO from the "core set" (e.g., PtGA for all) and domains that were not patient-reported. However, if their results were only presented as global results (e.g., ACR20 without reporting the constituent core set domains), the PRO included in the ACR criteria were not considered as reported.

Domains of health. PRO were classified by the authors according to a domain framework used previously^{6,9}. Questionnaires were divided into 2

parts. "Most frequently" reported questionnaires for each domain were defined as "major questionnaires." If the frequency of the report of questionnaire was more than 5% of articles, it was defined as a "secondary questionnaire."

Statistics. Results are presented as the frequency of domains that were reported and of each PRO within a domain. Statistical analysis was mainly descriptive, i.e., frequency of use of a PRO. Comparisons of frequency of PRO according to study designs were performed by the chi-square or Fisher's exact test. Data analyses used SPSS version 21.0.

RESULTS

Publications: selection process and description. Of the 479 publications identified by the literature search, 250 (52.2%) were included in our analysis. The majority of the 229 excluded publications either did not have any focus or reporting of PRO (n = 110) or were not about the selected disease (n = 74; Figure 1). Of the 250 publications remaining, 113 (45.2%) were RCT and 137 (54.8%) were other types of studies (open-label trial, prospective cohort, retrospective study, and other study designs).

The total number of patients included in the reports was 143,670, and the mean (SD) number of patients per article was 579 (1365). Mean age was 54.8 years (4.2), mean disease duration was 7.8 years (4.6), and 75.2% were women. The most commonly assessed treatments were disease-modifying antirheumatic drugs, either biological or conventional synthetic (n = 140, 63.2%).

Composite indices and response criteria reported across studies were the DAS and/or EULAR (n = 205, 82.0%), ACR (n = 83, 33.2%), SDAI (n = 40, 16.0%), and CDAI (n = 37, 14.8%), whereas none of these were reported in 38 studies (15.2%). Composite indices were more frequently used in RCT (90.3% in RCT vs 80.3% in other studies, p = 0.029), especially the ACR response (59.3% vs 11.7%, p < 0.0001) and SDAI score (21.2% vs 11.7%, p = 0.04).

PRO: overview. Across the 250 articles, 138 PRO measures were reported. The mean numbers of PRO per article was 2.7 (2.5), and the mean number of questionnaires used across the articles to report a specific domain was 9.9 (8.0). The distribution of all domains and measures are presented in Supplementary Table 1 (available from the authors on request). The 138 PRO instruments were spread across 14 domains of health, i.e., function, PtGA, pain, morning stiffness, HRQOL, utility, fatigue, self-reported painful joint count, psychological status, coping, productivity losses, well-being, sleep disturbance, and leisure. Physical function/disability was reported in 68.0% of studies, the vast majority using the Health Assessment Questionnaire (HAQ; 89.4%). PtGA was reported in 49.2%, mostly using visual analog scales (VAS) or numeric rating scales (NRS; 83.7%). Pain was reported in 40.0% of studies, predominantly also using VAS or NRS (89.0%; Table 1).

Generic HRQOL was evaluated in 46 studies (18.4%), most frequently using the Medical Outcomes Study Short Form-36 (SF-36; n = 29, 63.0%)¹⁷. HRQOL was more frequently reported in RCT than non-RCT studies (27.4% vs




Figure 1. Flow chart showing the selection of recent publications that reported PRO in rheumatoid arthritis. MeSH: Medical Subject Headings; PRO: patient-reported outcomes; RCT: randomized controlled trials.

10.9%, $p = 0.001$), as was the SF-36 (18.5% vs 6.8%, $p = 0.006$).

Fatigue was reported in 36 articles (14.4%). Fatigue VAS/NRS ($n = 18$, 50%) and the functional assessment of chronic illness therapy (FACIT)-fatigue ($n = 12$, 33.3%) were the main instruments used. Fatigue was more often reported in RCT than non-RCT studies (21.2% vs 8.8%, $p = 0.005$).

Stiffness was evaluated in 25 studies (10.0%), which was less frequently than in our previous SR (10.0% vs 26.6%) and was mostly assessed through “morning stiffness duration.”

Psychological status was reported in 24 articles (9.6%). The Hospital Anxiety and Depression Scale ($n = 6$, 25.0% of 24) and the Beck Depression Inventory ($n = 6$, 25.0% of 24) were the most frequently used questionnaires, but 23 different questionnaires were used to assess psychological status (Supplementary Table 1, available from the authors on request).

Assessments of productivity were reported in 16 studies (6.4%), primarily through employment status ($n = 8$, 50.0% of 16) and the Work Productivity and Activity Impairment questionnaire ($n = 4$, 25.0% of 16).

Utility was infrequently reported ($n = 13$, 5.2%) and mainly using the EQ-5D ($n = 11$, 84.6% of 13). Utility was reported less frequently than in our previous SR (5.2% vs 16.5%). The Short-Form Health Survey-6D was reported in only 1 study in our current analysis (7.7% of 13). Other domains such as sleep disturbance (2.4%), coping (2.0%), and leisure (0.4%) were infrequently reported.

DISCUSSION

In our present SR, the well-recognized RA core domains (function, pain, and PtGA)² were reported in a majority of RA studies, but other less-recognized domains of health were rarely reported (e.g., fatigue, sleep, productivity, HRQOL, coping, morning stiffness, and utility). Our current SR of RA

Table 1. Frequency of reporting of domains of health and questionnaires in the SR of 250 studies published from 2013–2014 in RA and for comparison purposes, similar results from an SR of 109 studies⁹. Values are n (%)** unless otherwise specified.

Domain of Health	Questionnaires used for Domains	Frequency of Reporting in 250 Studies	Frequency of Reporting in a Previous SR of 109 Studies
Function		170 (68.0)	91 (83.4)
	HAQ	152 (89.4)	67 (73.6)
	Modified HAQ*	13 (7.7)	14 (15.4)
PtGA		123 (49.2)	69 (63.3)
	PtGA VAS/NRS	103 (83.7)	53 (76.8)
	General health VAS/NRS*	23 (18.7)	10 (14.5)
Pain		100 (40.0)	61 (55.9)
	Pain VAS/NRS	89 (89.0)	52 (85.3)
Morning stiffness		25 (10.0)	29 (26.6)
	Duration	20 (80.0)	28 (96.6)
HRQOL		46 (18.4)	21 (19.2)
	SF-36	29 (63.0)	16 (76.2)
Fatigue		36 (14.4)	15 (13.7)
	Fatigue VAS/NRS	18 (50)	11 (73.3)
Utility		13 (5.2)	18 (16.5)
	EQ-5D	11 (84.6)	11 (61.1)
Self-reported painful joint count	None	7 (2.8)	10 (9.1)
Psychological status	None	24 (9.6)	8 (7.3)
Productivity losses	None	16 (6.4)	6 (5.5)
Well-being	None	2 (0.8)	4 (3.6)
Sleep disturbance	None	6 (2.4)	2 (1.8)
Coping	None	5 (2.0)	7 (6.4)
Leisure	None	1 (0.4)	1 (0.9)

* For the domains function and PtGA, there were secondary outcome measures used in more than 5% of cases.

** The n (%) given are n (%) of all studies for each domain, and n (%) of studies reporting this domain, for each questionnaire. SR: systematic review; RA: rheumatoid arthritis; HAQ: Health Assessment Questionnaire; PtGA: patient's global assessment; VAS: visual analog scale; NRS: numeric rating scale; HRQOL: health-related quality of life; SF-36: Medical Outcomes Study Short Form-36.

studies from the last 2 years shows that a large gap remains between the reporting of outcomes prioritized by physicians/researchers and the reporting of the range of areas of health that have been prioritized by patients with RA^{6,7,18}. Even though there has been an increasing call for the inclusion of PRO in RA research, there has been little change in their reporting in recent studies compared with our first SR 9 years ago of studies published between 2005 and 2007⁹, though of note, we have not analyzed publications between 2007 and 2013.

Compared with the previous SR, function, pain, and PtGA were also reported in the majority of RA studies in the 2005–2007 review⁹. This is in keeping with the recognition of these outcomes as core outcomes. On the other hand, other outcomes including the HRQOL and fatigue were not more frequently reported in the present SR than in the previous one. This is surprising given the importance of these outcomes for the patients and their recognition by the Outcome Measures in Rheumatology (OMERACT)¹⁹.

In total, 138 different PRO measures were used across 250 studies. Instruments to measure the existing RA Core Set PRO domains (function, pain, and PtGA) are well estab-

lished and relatively homogeneous². For example, the HAQ-Disability Index and less frequently the modified HAQ are used almost exclusively to assess physical function in patients with RA. In contrast, for domains such as fatigue, productivity, psychological status, sleeping, or coping, there is high heterogeneity among the instruments used for their measurement in the studies we reviewed, reflecting a lack of consensus on what needs to be measured in RA and the lack of optimal, appropriately validated instruments for most of these domains²⁰. In the case of psychological status, 23 different questionnaires were used across 24 studies, and their validity was rarely if ever demonstrated. For the assessment of HRQOL, the SF-36 was most commonly used: a universal, generic, copyrighted quality-of-life instrument. For fatigue, there was more consistency in the instruments used with the VAS/NRS and FACIT used most often, but the measurement properties of these instruments have limitations²¹, and newer fatigue measures for both RA disease-specific and other measures with better psychometric properties are being studied²². Composite PRO that combine a number of different RA-related symptoms and effects have also been developed including the Routine Assessment of Patient Index

Data 3²³ and the RA Impact of Disease score⁶, and are being included more frequently in assessments. With evolving guidelines for PRO development and validation using advanced psychometric methods²⁴, other measurement symptoms such as the PRO Measurement Information System²⁵ have potential for use in future investigations.

There were certain limitations to our SR. First, we only used PubMed as the search source, thus we may have missed abstract data (for instance, in EMBASE) or in other sources such as the US Food and Drug Administration or the European Medicines Agency reports and submissions. Second, our literature review spanned only 2 years and did not include extraction of all variables as has been recommended by groups such as the COSMIN (CONsensus-based Standards for the selection of health status Measurement Instruments)²⁶. However, it is important to recognize that the purpose of our review was to compare PRO collected during an earlier interval with a more recent time frame, which would be most appropriate using the same search variables. Moreover, it was not our intent to evaluate the degree of validation of individual PRO measures, but rather to report frequencies of reporting of different domains. Finally, it is important to recognize that although there has been increased recognition of including the patient perspective in RA research, there may be a considerable time lag between the design of a clinical trial, its completion, and the reporting of results. It would be interesting to compare in future studies the proportion of outcomes in studies that are laboratory clinician-reported versus patient-reported.

The existing RA Core Set PRO domains (function, pain, PtGA) are still a dominant part of RA studies and their measurement is generally reported using consistent instruments. Other domains that have been prioritized by patients including fatigue, productivity, sleep disturbance, and coping are infrequently reported, and when they are, there is tremendous heterogeneity in the specific instruments selected. Better understanding of the barriers to more comprehensive and consistent PRO collection requires additional studies, and further work by groups such as the OMERACT^{19,27} is needed to develop consensus on what domains should be collected and how to best measure them.

REFERENCES

1. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, et al. Health-related quality of life and estimates of utility in chronic kidney disease. *Kidney Int* 2005;68:2801-8.
2. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. *Ann Rheum Dis* 2008;67:1360-4.
3. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res* 2012;64:625-39.
4. Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. *Arthritis Rheum* 2011;63:3204-15.
5. Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, et al. Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. *Arthritis Care Res* 2012;64:206-14.
6. Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. *Ann Rheum Dis* 2009;68:1680-5.
7. van Tuyl LH, Hewlett S, Sadlonova M, Davis B, Flurey C, Hoogland W, et al. The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'. *Ann Rheum Dis* 2015;74:1004-10.
8. Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth TG, Alten R, Pohl C, et al; OMERACT RA Flare Working Group. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. *Ann Rheum Dis* 2012;71:1855-60.
9. Kalyoncu U, Dougados M, Daures JP, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. *Ann Rheum Dis* 2009;68:183-90.
10. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis [review]. *RMD Open* 2015;1:e000019.
11. Gossec L, Berenbaum F, Chauvin P, Lamiraud K, Russo-Marie F, Joubert JM, et al. Reporting of patient-perceived impact of rheumatoid arthritis and axial spondyloarthritis over 10 years: a systematic literature review. *Rheumatology* 2014;53:1274-81.
12. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44-8.
13. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38:727-35.
14. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum* 1996;39:34-40.
15. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology* 2003;42:244-57.
16. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. *Arthritis Res Ther* 2005;7:R796-806.
17. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. *Med Care* 1994;32:40-66.
18. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. *Arthritis Care Res* 2010;62:647-56.
19. Kirwan JR, Bartlett SJ, Beaton DE, Boers M, Bosworth A, Brooks PM, et al. Updating the OMERACT filter: implications for patient-reported outcomes. *J Rheumatol* 2014;41:1011-5.
20. Castrejón I, Gossec L, Carmona L. The EULAR Outcome Measures

- Library: an evolutionary database of validated patient-reported instruments. *Ann Rheum Dis* 2015;74:475-6.
21. Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. *Arthritis Rheum* 2007;57:429-39.
 22. Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAFMQ), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAFNRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACIT-F), Multi-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue Inventory (MFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProF), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). *Arthritis Care Res* 2011;63 Suppl 11:S263-86.
 23. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. *J Rheumatol* 2008;35:2136-47.
 24. Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. *Qual Life Res* 2013;22:1889-905.
 25. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. *Med Care* 2007;45 Suppl 1:S3-S11.
 26. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. *Qual Life Res* 2010;19:539-49.
 27. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol* 2014;67:745-53.